Merck, Gilead halt Phase 3 KEYNOTE-D46/EVOKE-03 lung cancer trial after PFS misses significance
Share
Listen to the news
Merck, Gilead halt Phase 3 KEYNOTE-D46/EVOKE-03 lung cancer trial after PFS misses significance
  • Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial in first-line metastatic non-small cell lung cancer.
  • The Trodelvy-Keytruda combination showed a directional improvement in delaying disease worsening, but missed the study’s primary efficacy bar.
  • An independent monitoring committee judged a meaningful survival benefit was unlikely, driving the decision to stop the study.
  • Safety matched the known profiles of both drugs, with no new signals flagged.
  • Results have not been presented yet; the companies plan to present the data at a future medical meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608789974) on June 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending